Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiology and Therapy
Published in: Cardiology and Therapy 1/2013

Open Access 01-06-2013 | Review

Balancing Antiplatelet and Anticoagulant Therapies in Patients with Cardiovascular Disease

Authors: Edward T. Carreras, Jessica L. Mega

Published in: Cardiology and Therapy | Issue 1/2013

Login to get access

Abstract

Anticoagulation is needed for stroke prevention in patients with atrial fibrillation. Antiplatelet therapy is essential for the prevention of stent thrombosis and the reduction of cardiovascular events in patients who undergo coronary stenting and suffer acute coronary syndromes. When these conditions overlap, the individual antithrombotic strategies are commonly combined, and the efficacy benefit of triple oral antithrombotic therapy is assumed to outweigh the bleeding risk based on the available data. Recent studies have investigated this topic further, including the first randomized controlled trial to address this issue. This new evidence challenges previous assumptions and may have implications for future practice and investigation.
Literature
1.
Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2013 update a report from the American Heart Association. Circulation. 2012;127:e6–245.PubMedCrossRef
2.
Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv. 2011;4:522–34.PubMedCrossRef
3.
You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th edn. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl 2):e531S–75S.PubMedCrossRef
4.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001;285:2864–70.PubMedCrossRef
5.
Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (active w): a randomised controlled trial. Lancet. 2006;367:1903–12.PubMedCrossRef
6.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.PubMedCrossRef
7.
Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the framingham heart study. Circulation. 2004;110:1042–6.PubMedCrossRef
8.
[No Authors Listed.] Collaborative overview of randomised trials of antiplatelet therapy–I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet trialists’ collaboration. BMJ. 1994;308:81–106.
9.
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. NEJM. 2001;345:494–502.PubMedCrossRef
10.
Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. NEJM. 1998;339:1665–71.PubMedCrossRef
11.
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. NEJM. 2009;361:1045–57.PubMedCrossRef
12.
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. NEJM. 2007;357:2001–15.PubMedCrossRef
13.
Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. NEJM. 2010;362:1374–82.PubMedCrossRef
14.
Valgimigli M, Campo G, Percoco G, et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention design and rationale for the prolonging dual-antiplatelet treatment after grading stent-induced intimal hyperplasia study (prodigy). Am Heart J. 2010;160:804–11.PubMedCrossRef
15.
Byrne RA, Schulz S, Mehilli J, et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the intracoronary stenting and antithrombotic regimen: safety and efficacy of 6 months dual antiplatelet therapy after drug-eluting stenting (ISAR-SAFE) study. Am Heart J. 2009;157:620–4.PubMedCrossRef
16.
Lemesle G, Paparoni F, Delhaye C, Bonello L, Lablanche JM. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: a review of the current guidelines and literature. Hosp Pract (Minneap). 2011;39:32–40.CrossRef
17.
Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143:241–50.PubMedCrossRef
18.
Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27:519–26.PubMedCrossRef
19.
Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. NEJM. 2002;347:969–74.PubMedCrossRef
20.
van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the aspect-2 study): a randomised controlled trial. Lancet. 2002;360:109–13.PubMedCrossRef
21.
Ruiz-Nodar JM, Marin F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;51:818–25.PubMedCrossRef
22.
Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol. 2006;18:162–4.PubMed
23.
DeEugenio D, Kolman L, DeCaro M, et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy. 2007;27:691–6.PubMedCrossRef
24.
Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28:726–32.PubMedCrossRef
25.
Sarafoff N, Ndrepepa G, Mehilli J, et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med. 2008;264:472–80.PubMedCrossRef
26.
Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008;102:1618–23.PubMedCrossRef
27.
Holmes DR Jr, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol. 2009;54:95–109.PubMedCrossRef
28.
Lip GY, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a consensus document of the european society of cardiology working group on thrombosis, endorsed by the european heart rhythm association (ehra) and the european association of percutaneous cardiovascular interventions (eapci). Eur Heart J. 2010;31:1311–8.PubMedCrossRef
29.
Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185–93.PubMedCrossRef
30.
Dewilde W, Berg JT. Design and rationale of the WOEST trial: What is the optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation and coronary stenting (WOEST). Am Heart J. 2009;158:713–8.PubMedCrossRef
31.
Dewilde W, Oirbans T, Verheugt F, et al. The WOEST trial—clinical trial results. Paper presented at: European Society of Cardiology Congress; Aug 28, 2012; Munich, Germany.
32.
Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107–15.PubMedCrossRef
33.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEJM. 2011;365:883–91.PubMedCrossRef
34.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEJM. 2009;361:1139–51.PubMedCrossRef
35.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. NEJM. 2011;365:981–92.PubMedCrossRef
36.
Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation. 2009;119:2877–85.PubMedCrossRef
37.
Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. NEJM. 2011;365:699–708.PubMedCrossRef
38.
Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase ii trial. Lancet. 2009;374:29–38.PubMedCrossRef
39.
Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. NEJM. 2012;366:9–19.PubMedCrossRef
Metadata
Title
Balancing Antiplatelet and Anticoagulant Therapies in Patients with Cardiovascular Disease
Authors
Edward T. Carreras
Jessica L. Mega
Publication date
01-06-2013
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 1/2013
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-013-0015-2

Other articles of this Issue 1/2013

Cardiology and Therapy 1/2013 Go to the issue

Review

Glycemic Control: A Combination of Lifestyle Management and the Use of Drugs

Review

The Resolute™ Integrity Zotarolimus-Eluting Stent in Coronary Artery Disease: A Review

Review

Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments

Review

Thrombin Receptor Antagonism in Antiplatelet Therapy

Case Report

An Extremely Rare Combination: Pneumopericardium, Pneumoperitoneum, and Subcutanous Emphysema—A Case Report

Review

Optimal Choice of Coronary Revascularization and Stent Type in Diabetic Patients with Coronary Artery Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits